Video

Next Steps for Wnt Research in Colorectal Cancer

Author(s):

Luke Dow, PhD, discusses the next steps for researching the Wnt pathway in colorectal cancer.

Luke Dow, PhD, assistant professor of biochemistry and medicine, Weill Cornell Medicine, discusses the next steps for researching the Wnt pathway in colorectal cancer.

Currently, Wnt research is being guided by the clinic, explains Dow. Researchers are looking at the types of alterations seen through genomic profiling and from early-phase clinical trials to understand what is working, says Dow. From there, clinically relevant questions can be addressed.

Researchers are focused on defining, from a genetic standpoint, who would be most susceptible to Wnt-targeted therapies as well as who may show complete resistance to targeted approaches, according to Dow. Then, a patient subset likely to respond to these compounds in the clinic can be defined, concludes Dow.

Related Videos
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS